FIGURE 2.
Maximum change in tumor burden in relapsed/refractory CLL patients treated with single-agent ibrutinib (PCYC-1102 trial) (From data presented at American Society of Hematology Annual Meeting, San Diego, California, December, 2011).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.